[Evaluation of Picibanil as an adjuvant chemotherapeutic agent].
D000276:Adjuvants, Immunologic; D000328:Adult; D000368:Aged; D001688:Biological Products / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D003520:Cyclophosphamide / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D010844:Picibanil / Q000008:administration & dosage / Q000627:therapeutic use*; D014750:Vincristine / Q000008:administration & dosage
D000276:Adjuvants, Immunologic; D001688:Biological Products; D010844:Picibanil; D014750:Vincristine; D003520:Cyclophosphamide; D005472:Fluorouracil; D008727:Methotrexate
Proba oceny preparatu Picibanil jako leku wspomagajacego chemioterapie.